[go: up one dir, main page]

WO2024023360A1 - Composés substitués par ip5 - Google Patents

Composés substitués par ip5 Download PDF

Info

Publication number
WO2024023360A1
WO2024023360A1 PCT/EP2023/071141 EP2023071141W WO2024023360A1 WO 2024023360 A1 WO2024023360 A1 WO 2024023360A1 EP 2023071141 W EP2023071141 W EP 2023071141W WO 2024023360 A1 WO2024023360 A1 WO 2024023360A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
salt
inositol
aspects
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/071141
Other languages
English (en)
Inventor
Carolina Salcedo Roca
María Del Mar PÉREZ FERRER
Miquel David FERRER REYNÉS
Mohamad Firas BASSISSI
Carme Serra Comas
Juan Lorenzo Catena Ruiz
Amadeu Llebaria Soldevila
Joan PERELLÓ BESTARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanifit Therapeutics SA
Original Assignee
Sanifit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics SA filed Critical Sanifit Therapeutics SA
Priority to EP23750984.9A priority Critical patent/EP4562019A1/fr
Priority to CN202380056920.2A priority patent/CN119630679A/zh
Priority to KR1020257006598A priority patent/KR20250049546A/ko
Priority to IL318651A priority patent/IL318651A/en
Priority to CA3263493A priority patent/CA3263493A1/fr
Priority to JP2025505402A priority patent/JP2025525098A/ja
Priority to AU2023313051A priority patent/AU2023313051A1/en
Publication of WO2024023360A1 publication Critical patent/WO2024023360A1/fr
Priority to MX2025001128A priority patent/MX2025001128A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings with more than one hydroxy group bound to the ring
    • C07C35/16—Inositols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/188—Unsaturated ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to IP5 substituted compounds, their processes of synthesis, and their uses.
  • HAP Hydroxyapatite
  • Caio(P04)6(OH)2 a calcium phosphate of formula Caio(P04)6(OH)2
  • IP5 pentaphosphate myo-inositol
  • WO2021219135, W02017098047, and W02020058321 describe the use of these compounds for the treatment of pathologies associated with calcium.
  • IP5 substituted derivatives that could be effective in inhibiting HAP formation and growth and/or pathological crystallization.
  • the present invention discloses a compound of general formula I: a pharmaceutically acceptable salt thereof, or a combination thereof, wherein
  • R 1 , R 2 , R 3 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 4 is a substituent group of formula II or formula III, or Ri, R2, R 3 , R 4 , and R 5 independently represent OPO 3 H 2 and Re is a substituent group of formula II or formula III, ii III
  • R 1 , R 3 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 2 is a substituent group of formula II or formula III,
  • R 1 , R 2 , R 3 , R 4 , and R 6 independently represent -OPO 3 H 2 and R 5 is a substituent group of formula II or formula III,
  • R 2 , R 3 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and Ri is a substituent group of formula II; or R 1 , R 2 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 3 is a substituent group of formula II or formula III, wherein, for formula II, n is an integer between 1 and 30, wherein the terminal group X is selected from the group consisting of -H, -OR, -NRR', -COOR, -CONRR', -NHCOR, - NHCOOR, -OCONR, -NHSO 2 R, -NHCONRR', halogen, -CF 3 , alkyl, alkenyl, alkynyl, carbocycle (saturated or unsaturated), and heterocycle (saturated or unsaturated), and wherein R and R' are H or an alkyl group, and wherein, for formula III, y and
  • the compound of formula I is selected from the group consisting of Compounds 1 to Compound 53.
  • the pharmaceutically acceptable salt is a sodium or magnesium salt.
  • the sodium salt is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt, decasodium salt or undecasodium salt.
  • the invention also provides a pharmaceutical composition comprising a compound of formula I disclosed above and at least one pharmaceutically acceptable excipient.
  • calcium salts/crystals e.g., calcium phosphates, hydroxyapatite (HAP)
  • the invention provides a method to treat or prevent a disease or condition associated with pathological crystallization in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutical composition of disclosed herein.
  • Also provided is a method to inhibit the progression of a crystallization process in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutical composition of disclosed herein.
  • the invention also provides a method to recover or increase blood perfusion in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutical composition of disclosed herein.
  • the subject is human.
  • the administration is topical, enteral or parenteral.
  • the parenteral administration is intravenous.
  • the intravenous administration is by bolus injection or by infusion.
  • the present invention also provides a kit or article of manufacture comprising at least one compound of formula I or a pharmaceutical composition comprising a compound of formula I and instructions for administration according to any method disclosed herein.
  • the kit or article of manufacture may also comprise at least one compound selected from the group consisting of the compounds listed in Table 1.
  • the present invention provides additionally a method for the manufacture of a compound of formula I (e.g., Compound 1 to Compound 53) which comprises using at least one compound selected from the group consisting of the compounds listed in Table 1.
  • FIG. 1A and Fig. IB present representative structures of Compounds I_A: IP5-4 substituted compounds.
  • FIG. 2A and Fig. 2B present representative structures of Compounds I_B: IP5-2 substituted compounds.
  • FIG. 3 presents representative structures of Compounds I_C: IP5-5 substituted compounds.
  • Fig. 4 presents representative structures of Compounds I_D: IP5-1 substituted compounds.
  • Fig. 5 is a schematic representation of synthesis Scheme 1.
  • Fig. 6 is a schematic representation of synthesis Scheme 2.
  • Fig. 7A and Fig. 7B are schematic representations of syntheses Scheme 3 and Scheme 6, respectively.
  • Fig. 8A and Fig. 8B are schematic representations of syntheses Scheme 4 and Scheme 7, respectively.
  • Fig. 9A and Fig. 9B are schematic representations of syntheses Scheme 5 and Scheme 8, respectively. Detailed description of the invention
  • IP5 substituted compounds are a compound of general formula I: a pharmaceutically acceptable salt thereof, or a combination thereof, wherein
  • R 1 , R 2 , R 3 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 4 is a substituent group of formula II or formula III, or Ri, R2, R 3 , R 4 , and R 5 independently represent - OPO 3 H 2 and R 6 is a substituent group of formula II or formula III, (See Fig. 1A, IB)
  • R 1 , R 3 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and R2 is a substituent group of formula II or formula III, (See Fig. 2A, 2B)
  • R 1 , R 2 , R 3 , R 4 , and R 6 independently represent -OPO 3 H 2 and R 5 is a substituent group of formula II or formula III, (See Fig. 3)
  • R 2 , R 3 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and Ri is a substituent group of formula II; or R 1 , R 2 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 3 is a substituent group of formula II or formula III (See Fig.
  • n is an integer between 1 and 30, wherein the terminal group X is selected from the group consisting of -H, -OR, -NRR', -COOR, -CONRR', -NHCOR, - NHCOOR, -OCONR, -NHSO 2 R, -NHCONRR', halogen, -CF 3 , alkyl, alkenyl, alkynyl, carbocycle (saturated or unsaturated), and heterocycle (saturated or unsaturated), and wherein R and R' are H or an alkyl group, and wherein, for formula III, y and y’ are an integer between 0 and 10, wherein Cy is a cyclic linker, wherein the terminal group Z is selected from the group consisting of alkyl, -COR, -OR, -NRR', -COOR, -CONRR', - NHCOR, -NHCOOR, -OCONR -NHSO
  • the IP5 substituted compound is a sodium or magnesium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt, decasodium salt or undecasodium salt.
  • the invention includes aspects in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
  • the invention includes aspects in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
  • the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone).
  • the term “and/or” as used in a phrase such as "A, B, and/or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
  • the term “approximately,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term “approximately” refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
  • Bolus administration As used herein, the terms “bolus administration” and “bolus injection” refer a fast intravenous injection lasting less than 10 seconds, or an intravenous infusion lasting less than 3 minutes.
  • Compound As used herein, the term “compound,” is meant to include any and all free bases, isomers, and isotopes of the structure depicted. As used herein, the term “isomer” means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound. Compounds can include one or more chiral centers and/or double bonds and can thus exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis/trans isomers).
  • double-bond isomers i.e., geometric E/Z isomers
  • diastereomers e.g., enantiomers (i.e., (+) or (-) or cis/trans isomers).
  • the present invention encompasses any and all isomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures (e.g., racemates). Enantiomeric and stereomeric mixtures of compounds and means of resolving them into their component enantiomers or stereoisomers are well- known.
  • a compound, salt, or complex of the present invention can be prepared in combination with solvent or water molecules to form solvates and hydrates by routine methods.
  • the term compound is used to refer to an IP5 substituted compound of the present invention.
  • Effective amount As used herein, the term "effective amount" of a therapeutic agent, in reference to (i) an IP5 substituted compound of the present invention, (ii) any dosage form, pharmaceutical composition, or formulation disclosed herein comprising at least one IP5 substituted compound of the present invention, or (iii) a combination of an IP5 substituted compound of the present invention with one or more additional therapeutic agents), is that amount sufficient to effect beneficial or desired results.
  • the beneficial or desired results are, for example, clinical results, and, as such, an "effective amount” depends upon the context in which it is being applied.
  • the term “effective amount” can be used interchangeably with “effective dose,” “therapeutically effective amount,” or “therapeutically effective dose.”
  • an effective amount relates to the specific use of an IP5 substituted compound.
  • an IP5 substituted compound when used to inhibit the formation or growth of a calcium salt/crystal (e.g., a calcium phosphate, HAP), an effective amount would be an amount of the IP5 substituted compound capable of achieving the desired effect (e.g., the reduction of HAP crystallization/formation in blood serum or plasma).
  • a calcium salt/crystal e.g., a calcium phosphate, HAP
  • Enteral administration refers to any administration of an IP5 substituted compound of the present invention or a pharmaceutical composition comprising said compound via the gastrointestinal tract. Enteral administration includes, but is not limited to, the oral, sublingual, and rectal routes of administration.
  • Prophylaxis refers to a measure taken to maintain health and prevent or delay the onset of a disease or condition or to mitigate its extent and/or severity of the symptoms.
  • a prophylactic use of a therapeutic agent disclosed herein for example, (i) an IP5 substituted compound of the present invention, or (ii) a combination thereof, or (iii) any dosage form comprising at least one IP5 substituted compound of the present invention, or (iv) any formulation comprising at least one IP5 substituted compound of the present invention, or a (v) combination of an IP5 substituted compound of the present invention with one or more additional therapeutic agents, corresponds to that amount sufficient to effect beneficial or desired results.
  • any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
  • IP5 substituted, compounds of the present invention refers to a compound of formula I wherein its substituents are those disclosed in compound Families I_A, I_B, I_C, and I_D described in detail below, and salts thereof (e.g., pharmaceutically acceptable salts thereof).
  • the term IP5 substituted compound of the present invention encompasses Compounds 1 to 53, any salt thereof (e.g., a sodium salt), and any combination thereof.
  • IP5 substituted compound of the present invention encompasses a compound of formula I which is an intermediate in the synthesis of Compounds 1 to 53, e.g., a compound selected from the group consisting of the compounds listed in Table 1, any salt thereof (e.g., a sodium salt), and any combination thereof.
  • IP5 substituted compound of the present invention encompasses a compound of formula I which is Compound 1 to Compound 53 and a compound selected from the group consisting of the compounds listed in Table 1, any salt thereof (e.g., a sodium salt), and any combination thereof.
  • Group consisting of Compound 1 to Compound 53 refers to a group of compounds that comprises Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, and 53.
  • the group consisting of Compound 1 to Compound 53 also comprises combinations thereof.
  • a combination of compounds from the group consisting of Compound 1 to Compound 53 can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more compounds from the group consisting of Compound 1 to Compound 53.
  • Group consisting of the compounds listed in Table 1 refers to a group of intermediate compounds used, e.g., for the synthesis of an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) i.e., Intermediates II_A, II_B, II_B’, II_C, and II_D, Intermediates III_A, III_B, III_C, and III_D, Intermediates IV_A, IV_B, IV_C, and IV_D, Intermediates V_A, V_B, V_C and V_D, Intermediates VI_A, Intermediates VII_A, Intermediates VIII_B and VIII B’, Intermediates IX_D and Intermediates X_D.
  • an IP5 substituted compound of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • Intermediates II_A, II_B, II_B’, II_C, and II_D Intermediates III_A,
  • the group consisting of the compounds listed in Table 1 also comprises combinations thereof.
  • a combination of compounds from the group consisting of the compounds listed in Table 1 can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more compounds from the group consisting of the compounds listed in Table 1.
  • Non-bolus administration refers to an intravenous injection lasting 10 or more seconds, or an intravenous infusion lasting 3 or more minutes.
  • parenteral administration refers to the administration of an IP5 substituted compound of the present invention characterized by the physical breaching of a tissue of a subject and the administration of the compound through said breach in the tissue.
  • Parenteral administration includes, but is not limited to, the administration of an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) or a pharmaceutical composition comprising the compound, by the application of the compound or the composition through, for instance, a surgical incision or through a tissue-penetrating non-surgical wound.
  • parenteral administration includes, but is not limited to, the epidural, intraarterial, intradermal, intrathecal, intramuscular, intraperitoneal, intrastemal injection, intravascular, intravenous, intravenous infusion, spinal, subcutaneous, and subcutaneous depot routes of administration.
  • Subject By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired.
  • Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; bears, food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, hamsters and guinea pigs; and so on.
  • the mam include, but
  • the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
  • One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result.
  • the term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
  • Therapeutic agent' is used in a broad sense to include a composition comprising an IP5 substituted compound of the present invention that can provide a significant therapeutic benefit to a subject in need thereof.
  • the subject in need thereof is a subject suffering or at risk of developing a disease or condition associated to pathological crystallization (e.g., a calcium phosphate or HAP crystallization).
  • a therapeutic agent according to the present invention can be an IP5 substituted compound of the present invention, alone or in combination with one or more additional therapeutic agents, that is administered in an amount sufficient to effect beneficial or desired results.
  • therapeutic agent also encompasses prophylactic, diagnostic or imaging agents comprising an IP5 substituted compound of the present invention, wherein the therapeutic agent is administered (i.e., topically, enterally or parenterally).
  • therapeutic agents of the present invention include agents that inhibit the formation or growth of calcium salts/crystals (e.g., calcium phosphates, HAP) and/or can ameliorate and/or prevent any symptom associated with pathological crystallization.
  • Topical administration refers to any administration of an IP5 substituted compound of the present invention or a pharmaceutical composition comprising said compound by applying the compound or composition to a particular place on or in the body, such as the skin or a mucous membrane.
  • Topical administration includes, but is not limited to, the aural, cutaneous, nasal, transdermal, urethral, vaginal, and urethral routes of administration.
  • Treating, treatment, therapy refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, reducing incidence of one or more symptoms or features of disease, or any combination thereof.
  • a treatment comprising an IP5 substituted compound of the present invention can be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition, and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of, e.g., (i) decreasing the risk of developing a pathology associated with the disease, disorder, and/or condition, (ii) delaying the onset of the disease, disorder, and/or condition, or a pathology associated with said disease, disorder, and/or condition, or (iii) mitigating the symptoms and/or sequels of the disease, disorder, and/or condition or a pathology associated with said disease, disorder, and/or condition.
  • treatment refers to countering the effects caused as a result of the disease or pathological condition of interest in a subject including (i) inhibiting the disease or pathological condition, in other words, slowing or stopping the development or progression thereof; (ii) relieving the disease or pathological condition, in other words, causing said disease or pathological condition, or the symptoms thereof, to regress; (iii) stabilizing the disease or pathological condition, and (iv) any combination thereof.
  • ug, uM, uL As used herein, the terms “ug,” “uM,” and “uL” are used interchangeably with “pg,” “pM,” and “pL” respectively.
  • IP5 substituted compounds are a compound of general formula I: a pharmaceutically acceptable salt thereof, or a combination thereof, wherein
  • R 1 , R 2 , R 3 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 4 is a substituent group of formula II or formula III, or Ri, R2, R 3 , R 4 , and R 5 independently represent - OPO 3 H 2 and Re is a substituent group of formula II or formula III,
  • R 1 , R 3 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and R2 is a substituent group of formula II or formula III,
  • R 1 , R 2 , R 3 , R 4 , and R 6 independently represent -OPO 3 H 2 and R 5 is a substituent group of formula II or formula III,
  • R 2 , R 3 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and Ri is a substituent group of formula II; or R 1 , R 2 , R 4 , R 5 , and R 6 independently represent -OPO 3 H 2 and R 3 is a substituent group of formula II or formula III,
  • n is an integer between 1 and 30, wherein the terminal group X is selected from the group consisting of -H, -OR, -NRR', -COOR, -CONRR', - NHCOR, -NHCOOR, -OCONR, -NHSO 2 R, -NHCONRR', halogen, -CF 3 , alkyl, alkenyl, alkynyl, carbocycle (saturated or unsaturated), and heterocycle (saturated or unsaturated), and wherein R and R' are H or an alkyl group, and wherein, for formula III, y and y’ are an integer between 0 and 10, wherein Cy is a cyclic linker, wherein the terminal group Z is selected from the group consisting of alkyl, -COR, -OR, -NRR', -COOR, -CONRR', - NHCOR, -NHCOOR, -OCONR -NHSO
  • an IP5 substituted compound of the present invention can be, for example, a tetraionic salt (e.g., tetrasodium salt), a pentaionic salt (e.g., pentasodium salt), a hexaionic salt (e.g., hexasodium salt), a heptaionic salt (e.g., heptasodium salt), an octaionic salt (e.g., octasodium salt), a nonaionic salt (e.g., nonasodium salt), a decaionic salt (e.g., decasodium salt) or a undecaionic salt (e.g., undecasodium salt).
  • a tetraionic salt e.g., tetrasodium salt
  • a pentaionic salt e.g., pentasodium salt
  • a hexaionic salt
  • the presence of additional negatively charges group in a IP5 substituted compounds can lead to the formation of complexes with additional ions.
  • the IP5 substituted compound of the present invention is a sodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt, decasodium or undecasodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt.
  • the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • Formula I and the rest of formulas presented in the invention are meant to encompass any isomers of the compounds covered thereby.
  • alkenyl or “alkenyl chain” in the context of the present invention refers to a linear or branched alkyl chain (e.g., containing between 2 and 10 carbon atoms) containing one or more double bonds, either substituted or non-substituted. Examples include, among others, ethenyl, 1 -propenyl, 2-propenyl, isopropenyl. 1-butenyl, 2- butenyl, 3-butenyl, and 1,3-butadienyl.
  • alkyl or "alkyl chain” in the context of the present invention refers to a hydrocarbon moiety, which can be saturated, partially unsaturated, linear, branched, cyclic or cyclic with linear or branched side chains containing from 1 to 30 carbon atoms. Examples include but are not limited are to C1-C4 alkyls such as methyl, ethyl, propyl, isopropyl, n- or isobutyl, and cycloalkyl such as cyclohexyl.
  • alkyl can extend to alkyl groups linked or bridged by hetero atoms. Hetero atoms in the context of the present invention are nitrogen (N), sulfur (S), oxygen (O), and halogen.
  • alkynyl or “alkynyl chain” in the context of the present invention refers to a linear or branched alkyl chain (e.g., containing between 2 and 10 carbon atoms) containing one or more triple bonds, either substituted or non-substituted. Examples include, among others, ethynyl, propynyl, 1-butynyl, and 3-butynyl.
  • An "amine function” or “amine group” is a function NRR’, with R and R’ selected independently, e.g., from hydrogen (-H) and an alkyl group such as an Ci-C n alkyl, wherein n is and integer between 0 and 30.
  • a "hydroxy function" or "hydroxy group” is OH.
  • a “carboxylic acid function” or “carboxylic acid group” is COOH or its anion, COO .
  • a “carboxylic amide” is CONRR’ or NCOR, with R and R’ selected independently, e.g., from hydrogen (-H) and an alkyl group such as an Ci-C n alkyl, wherein n is and integer between 0 and 20.
  • a “carbocycle” refers to a three- to 10-membered carbocyclic ring that can be saturated, partially unsaturated or aromatic (e.g., phenyl, cyclopentyl, cyclopropyl) and which is bound to the rest of the molecule via any available C atom.
  • a "heterocycle” refers to a three- to 10-membered cyclic ring containing at least one heteroatom selected from among N, O, and S, that can be saturated, partially unsaturated or aromatic (e.g., triazole, piperazine, pyrazole) and which is bound to the rest of the molecule via any available C atom or N atom.
  • the term includes heterocycle rings substituted with one or more halogen atoms.
  • a "Cy” refers to a cyclic linker comprising a carbocycle or a heterocycle.
  • Examples of carbocycles and heterocycles include, among others, 1,3-phenyl, 1,4-phenyl, naphthyl, thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3- triazolyl, 1,2,4-triazolyl, tetrazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, piperazyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzimidazolyl, benzofuranyl, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, benzothiazolyl, cyclopropyl, cyclobutyl, cyclopen
  • a "halogen” group refers to fluorine, chlorine, bromine or iodine.
  • -OPO3 2 in the context of the present invention refers also indistinctly to -OPO 3 H + and -OPO 3 H 2 .
  • IP5 substituted compounds of the present invention or intermediate compounds disclosed herein can be detected and/or quantified using the methods disclosed in US9612250. See also, US8377909, US8778912 and US20070066574.
  • IP5 substituted compounds of the present invention can be present in any form commonly used in pharmaceutical technology. Particular aspects include, but are not limited to, the sodium salt, magnesium salt, potassium salt, ammonium salt, free acid, or a mixture of the preceding forms. Other pharmaceutically acceptable salts are known to the skilled artisan and can be obtained by methods previously described (Haynes M, el al., J. Pharmaceutical Sci. 2005; 94:2111-2120.
  • an IP5 substituted compound of the present invention comprises or consists of an IP5 substituted compound selected from the group consisting of Compounds 1 to 53 and combinations thereof.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 1.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 2.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 3.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 4.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 5.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 6.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 7. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 8. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 9. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 10. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 11. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 12. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 13. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 14.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 15. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 16. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 17. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 18. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 19. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 20. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 21. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 22.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 23. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 24. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 25. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 26. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 27. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 28. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 29. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 30.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 31. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 32. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 33. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 34. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 35. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 36. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 37. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 38.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 39. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 40. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 41. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 42. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 43. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 44. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 45. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 46.
  • an IP5 substituted compound of the present invention comprises or consists of Compound 47. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 48. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 49. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 50. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 51. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 52. In some aspects, an IP5 substituted compound of the present invention comprises or consists of Compound 53.
  • IP5 substituted compounds of the present invention are disclosed in myo form.
  • the present invention also provides chemical intermediate compounds useful in the preparations of IP5 substituted compound of the present invention (e.g., Compound 1 to Compound 53).
  • such intermediates are the compounds listed in Table 1.
  • An intermediate compound disclosed herein can be converted to an IP5 substituted compound of the present invention by utilizing the procedures described herein.
  • the present invention provides methods to produce an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compounds 1 to 53) comprising utilizing an intermediate compound selected from the group consisting of the compounds listed in Table 1.
  • the present invention also provides methods of producing the intermediate compounds disclosed herein. Accordingly, the present invention provides methods of producing intermediates compounds selected from the group consisting of the compounds listed in Table 1 for producing IP5 substituted compounds of the present invention (e.g., a compound selected from the group consisting of Compounds 1 to 53).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula:
  • n is an integer between 1 and 30, alkyl is CH 2 and X is -H, -OH, -OMe, pyrazole, triazole, -COOH, CONRR', -NHCOR, -NHCOOR, -OCONR, -NHSO 2 R, -NHCONRR', -CF 3 , alkyl, cyclopropane, cyclopentane or pyrazole. See Fig. 1A.
  • n is an integer between 1 and 20.
  • n is an integer between 1 and 10.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
  • the IP5 substituted compound is a sodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound is an octasodium salt.
  • n is 5, alkyl is CH 2 and X is -H (Compound 1).
  • n is 3, alkyl is CH 2 and X is -H (Compound 24).
  • n is 1, alkyl is CH 2 and X is -H (Compound 22).
  • n is 5, alkyl is CH 2 and X is -OH (Compound 2).
  • n is 10, alkyl is CH 2 and X is -OH (Compound 21).
  • n is 5, alkyl is CH 2 and X is -OMe (Compound 3).
  • n 7 alkyl is CH 2 and X is -OMe (Compound 23). In some aspects, n is 5, alkyl is CH 2 and X is -COOH (Compound 4). In some aspects, n is 10, alkyl is CH 2 and X is - COOH (Compound 20). In some aspects, n is 3, alkyl is CH 2 and X is - CH(CH 3 ) 2 (Compound 12). In some aspects, n is 5, alkyl is CH 2 and X is -CF 3 (Compound 13). In some aspects, n is 5, alkyl is CH 2 and X is -NHCOMe (Compound 19).
  • n is 2, alkyl is CH 2 and X is cyclopentane (Compound 16). In some aspects, n is 2, alkyl is CH 2 and X is cyclopropane (Compound 17). In some aspects, n is 5, alkyl is CH 2 and X is pyrazole (Compound 18). In some aspects, n is 5, alkyl is CH 2 and X is - CONH 2 (Compound 33).
  • n is an integer between 3 and 30, alkyl is CH 2 and X is an amine group. See Fig. 1A; Wang, 2014, supra. In some aspects, n is an integer between 3 and 20. In some aspects, n is an integer between 3 and 10. In some aspects, n is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
  • the IP5 substituted compound is a sodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is an octasodium salt. In some aspects, n is 3, alkyl is CH 2 and X is -NH2 (Compound 27). In some aspects, n is 6, alkyl is CH 2 and X is -NH 2 (Compound 28).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula: v
  • n is an integer between 1 and 30, alkyl is CH 2 and X is -H, -OH, -OMe, amine group, pyrazole, triazole, -COOH, CONRR', -NHCOR, -NHCOOR, -OCONR, - NHSO 2 R, -NHCONRR', -CF 3 , cyclopropane, cyclopentane, pyrazole or alkynyl group. See Fig. 2A.
  • n is an integer between 1 and 20. In some aspects, n is an integer between 1 and 10.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.
  • the IP5 substituted compound is a sodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt.
  • the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is an octasodium salt.
  • n is 5, alkyl is CH 2 and X is -H (Compound 6). In some aspects, n is 3, alkyl is CH 2 and X is -H (Compound 34). In some aspects, n is 5, alkyl is CH 2 and X is -OH (Compound 40). In some aspects, n is 5, alkyl is CH 2 and X is -OMe (Compound 7).
  • n 9, alkyl is CH 2 and X is -OMe (Compound 8). In some aspects, n is 19, alkyl is CH 2 and X is -OMe (Compound 9). In some aspects, n is 29, alkyl is CH 2 and X is -OMe (Compound 10). In some aspects, n is 5, alkyl is CH 2 and X is -NHCOMe (Compound 35). In some aspects, n is 5, alkyl is CH 2 and X is -CF 3 (Compound 36). In some aspects, n is 5, alkyl is CH 2 and X is - CONH 2 (Compound 37).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula:
  • n is an integer between 1 and 30, alkyl is CH 2 and X is -H, -OH, -OMe, amine group, pyrazole, triazole, -COOH, CONRR', -NHCOR, -NHCOOR, -OCONR, - NHSO 2 R, -NHCONRR', -CF 3 , cyclopropane, cyclopentane or pyrazole. See Fig. 3A.
  • n is an integer between 1 and 20.
  • n is an integer between 1 and 10.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
  • the IP5 substituted compound is a sodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound is an octasodium salt.
  • n is 3, alkyl is CH 2 and X is -H (Compound 29).
  • n is 9, alkyl is CH 2 and X is -OMe (Compound 31).
  • n is 5, alkyl is CH 2 and X is -OMe (Compound 44).
  • n is 5, alkyl is CH 2 and X is -CF 3 (Compound 45).
  • n is 2, alkyl is CH 2 and X is cyclopropane (Compound 30).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula:
  • n is an integer between 1 and 30, alkyl is CH 2 and X is -H, -OH, -OMe, amine group, pyrazole, triazole, -COOH, CONRR', -NHCOR, -NHCOOR, -OCONR, - NHSO 2 R, -NHCONRR', -CF 3 , cyclopropane, cyclopentane or pyrazole. See Fig. 4.
  • n is an integer between 1 and 20.
  • n is an integer between 1 and 10.
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
  • the IP5 substituted compound is a sodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound is an octasodium salt.
  • n 3, alkyl is CH 2 and X is -H (Compound 32).
  • n 9, alkyl is CH 2 and X is -OMe (Compound 47).
  • n 5, alkyl is CH 2 and X is -NHCOMe (Compound 49).
  • n 5, alkyl is CH 2 and X is -CF 3 (Compound 50).
  • n is 2, alkyl is CH 2 and X is cyclopropane (Compound 48).
  • n is 2, alkyl is CH 2 and X is cyclopentane (Compound 51).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula:
  • y and y' is an integer between 0 and 10
  • alkyl is CH 2
  • Cy is selected from the group consisting of 1,3-substituted phenyl, 1,4-substituted phenyl, piperazine, triazole- 1, and triazole-2
  • Z is selected from the group consisting of -CH3, -OMe, - CF 3 , COCH 3 , and -COOH 3 .
  • the IP5 substituted compound is a sodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound an octasodium salt or nonasodium salt.
  • y or y' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • y is 3, y' is 0, alkyl is CH 2 , Cy is 1,4-substituted phenyl, and Z is -CH3 (Compound 11).
  • y is 3, y' is 0, alkyl is CH 2 , Cy is 1,4-substituted phenyl, and Z is - OMe (Compound 14).
  • y is 3, y' is 0, alkyl is CH 2 , Cy is 1,3-substituted phenyl, and Z is -CF 3 (Compound 15).
  • y is 2, y' is 0, alkyl is CH 2 , Cy is piperazine, and Z is -COCH 3 (Compound 5).
  • y is 3, y' is 2, alkyl is CH 2 , Cy is triazole-1, and Z is -COOH (Compound 25).
  • y is 6, y' is 0, alkyl is CH 2 , Cy is triazole-1, and Z is -COOH (Compound 26).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula:
  • y and y' is an integer between 0 and 10
  • alkyl is CH 2
  • Cy is selected from the group consisting of 1,3-substituted phenyl, 1,4-substituted phenyl, piperazine, triazole- 1, and triazole-2
  • Z is selected from the group consisting of -CH3, -OMe, - CF 3 , COCH 3 , and -COOH 3 .
  • the IP5 substituted compound is a sodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound an octasodium salt or nonasodium salt.
  • y or y' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • y is 5, y' is 1, alkyl is CH 2 , Cy is triazole-1, and Z is -OMe (Compound 41).
  • y is 1, y' is 2, alkyl is CH 2 , Cy is triazole-2, and Z is -COOH (Compound 46).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula: [95] wherein y and y' is an integer between 0 and 10, alkyl is CH 2 , Cy is selected from the group consisting of 1,3-substituted phenyl, 1,4-substituted phenyl, piperazine, triazole- 1, and triazole-2, and Z is selected from the group consisting of -CH3, -OMe, - CF 3 , COCH 3 , and -COOH 3 . See Fig. 3.
  • the IP5 substituted compound is a sodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound an octasodium salt or nonasodium salt.
  • y or y' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • y is 5, y' is 1, alkyl is CH 2 , Cy is triazole-1, and Z is -OMe (Compound 42).
  • an IP5 substituted compound of the present invention comprises or consists of a compound of the following formula:
  • y and y' is an integer between 0 and 10
  • alkyl is CH 2
  • Cy is selected from the group consisting of 1,3-substituted phenyl, 1,4-substituted phenyl, piperazine, triazole-1, and triazole-2
  • Z is selected from the group consisting of -CH3, -OMe, - CF 3 , COCH 3 , and -COOH 3 .
  • the IP5 substituted compound is a sodium salt.
  • the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt, octasodium salt, nonasodium salt or decasodium salt. In some aspects, the IP5 substituted compound is a tetrasodium salt, pentasodium salt, hexasodium salt, heptasodium salt or octasodium salt. In some aspects, the IP5 substituted compound is a hexasodium salt, octasodium salt, nonasodium salt or decasodium salt.
  • the IP5 substituted compound an octasodium salt or nonasodium salt.
  • y or y' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • y is 5, y' is 1, alkyl is CH 2 , Cy is triazole-1, and Z is -OMe (Compound 52).
  • y is 1, y' is 2, alkyl is CH 2 , Cy is triazole-2, and Z is -COOH (Compound 53).
  • IP5 substituted compounds of the present invention and intermediates for their synthesis can be synthesized by using the methods described herein, as well as other processes known in the field of the organic chemistry.
  • the methods include, but are not limited to, the general procedures shown in the synthesis Schemes 1, 2, 3, 4, 5, 6, 7 and 8 described herein.
  • the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 1 disclosed below.
  • the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 2 disclosed below.
  • the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 3 disclosed below.
  • the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 4 disclosed below. In some aspects, the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 5 disclosed below. In some aspects, the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 6 disclosed below. In some aspects, the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 7 disclosed below. In some aspects, the present invention provides a method to manufacture an IP5 substituted compound of the present invention comprising applying synthetic Scheme 8 disclosed below.
  • the present invention provides a method to manufacture an intermediate for the synthesis of an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) comprising applying any of synthetic Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme, 5, Scheme 6, Scheme 7 or Scheme 8 disclosed below as applicable.
  • the IP5 substituted compounds of the present invention can be obtained by deprotecting the intermediates of formula IV_A (Scheme 1).
  • the "protective group” or GP can be, without limitation, benzyl, levulinylbenzyl, tert-butyl, o,o ’-xylenyl (by union of 2 PG in the same phosphate), 9- fluorenylmethyl, cyanoethyl and other suitable protective groups in each case.
  • Intermediates of formula IV_A may be achieved by phosphorylation of an intermediate of formula III_A according to procedures described in the literature such as reaction with a phosphoroamidite derivative and subsequent oxidation.
  • intermediates of formula III_A can be obtained by hydrolysis in acid media of intermediates of formula II_A.
  • intermediates of formula II_A may be obtained by alkylation of intermediate (2) with an alkylating agent.
  • Preparation of (2) was previously described in the literature (Martin S, et al., J Org Chem 1994; 59(17): 4805-4820, Kardivel M, Org Biomol Chem 2008; 6(11): 1966-1972).
  • the "leaving Group” or LG may be, without limitation, chloride, bromide, iodide, toluenesulfonyl (Ts) or methylsulfonyl (Ms). See Fig. 5.
  • Scheme 2 As an alternative to Scheme 1, when R 4 or Re contain a substituted 1,2,3-triazole, compounds of formula I_A can be obtained by following the alternative route described in Scheme 2. In this way, intermediates of formula III_A can be obtained via a click reaction by using as starting materials an intermediate of formula VI_A and an alkynyl “click agent”. Intermediates VI_A can be achieved by alkylation and hydrolysis of intermediate 2 with an appropriate reagent. As another alternative, when R 4 or Re contain a terminal amine group, compounds of formula I_A can be obtained by phosphorylation of compound VI_A in order to obtain compounds VII- A, and by the subsequent deprotection/reduction of such compounds. See Fig. 6.
  • Scheme 3 Compounds I_B may be obtained using a similar synthetic route used for compounds I_A.
  • compounds I_B may be obtained by deprotecting intermediates of formula IV_B (Scheme 3).
  • Intermediates of formula IV_B may be attained by phosphorylating an intermediate of formula III_B.
  • intermediates of formula III_B can be obtained by the hydrolysis in acid media of intermediates of formula II_B or VIII_B.
  • Intermediates of formula VIII_B may be achieved by the debenzylation of intermediates II_B’.
  • intermediates of formula II_B or B’ may be obtained by the alkylation of intermediates (3) or (4), respectively, with an alkylating agent.
  • Scheme 4 Compounds I_C can be obtained by the deprotection of intermediates of formula IV_C (Scheme 4). Intermediates of formula IV_C may be achieved phosphorylating intermediates of formula IV_C. Intermediates of formula III_C can be obtained by the debenzylation of intermediates II_C. Finally, intermediates of formula II_C may be obtained by the alkylation of intermediate (33) with an appropriate alkylating agent. Preparation of (33) has been previously described in the art (Phenix C. et al., ChemBioChem 2008; 9(10): 1591-1602). See Fig. 8A.
  • Scheme 6 As an alternative to Scheme 3, when R2 contain a substituted 1,2,3- triazole or an acylamine, compounds of formula I_B can be obtained by following the alternative route described in Scheme 6. In this way, intermediates of formula III_B can be also obtained via a click reaction by using as starting materials an azide intermediate of formula V_B and an alkynyl “click agent”. Intermediate V_B can be achieved by alkylation of intermediate 3 with an appropriate reagent. As another alternative, when R2 contains a terminal acylamine group, compounds of formula III_B can be obtained by amidation of the corresponding amino compound III_B. See Fig. 7B.
  • Scheme 7 As an alternative to Scheme 4, when R 5 contain a substituted 1,2,3- triazole, compounds of formula I_C can be obtained by following the alternative route described in Scheme 7. In this way, intermediates of formula II_C can be also obtained via a click reaction by using as starting materials an azide intermediate of formula V_C and an alkynyl “click agent”. Intermediate V_C can be achieved by alkylation of intermediate 33 with an appropriate reagent. See Fig. 8B.
  • IP5 substituted compounds of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • any exemplary IPS substituted compound of the present invention in the myo conformation is not limited to the representative conformation displayed.
  • Compounds 1 to S3 and the intermediates presented herein are in the myo conformation.
  • the natural myo isomer has a structure in which five of the six hydroxyls (the first, third, fourth, fifth, and sixth) are equatorial, whereas the second hydroxyl group is axial.
  • the present invention also provides methods to manufacture a medicament for the treatment of pathological crystallization comprising using an intermediate compound selected from the group consisting of the compounds listed in Table 1. Also provided is a compound of formula I (e.g., selected from the group consisting of Compound 1 to Compound 53) for use as a medicament. Also provided is the use of a compound of formula I (e.g., selected from the group consisting of Compound 1 to Compound 53) for the manufacture of a medicament for the prevention or treatment of a disease related to pathological crystallization.
  • a compound of formula I e.g., selected from the group consisting of Compound 1 to Compound 53
  • the present invention also provides pharmaceutical compositions for use in the methods for the prevention and/or treatment of diseases and conditions disclosed herein (e.g., pathological crystallizations), wherein the pharmaceutical composition comprises at least one IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53).
  • the pharmaceutical composition comprises an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) alone or together with one or more pharmaceutically acceptable excipients or carriers.
  • excipient refers to a substance which helps absorption of the elements of the pharmaceutical composition, stabilizes said elements, activates or helps preparation of the composition.
  • excipients used in parenteral formulations include, but are not limited to, antimicrobial agents (e.g., benzalkonium chloride, metacresol, thimerosal), co-solvents (e.g., ethanol), buffers, tonicity agents (e.g., NaCl) and pH adjusting factors (e.g., carbonate, citrate, phosphate solutions).
  • the "pharmaceutically acceptable vehicle” is a substance used in the composition to dilute any of the components contained therein to a determined volume or weight (e.g., a 0.9% (w/v) NaCl aqueous solution).
  • the pharmaceutically acceptable vehicle is an inert substance or a substance with an analogous action to any of the elements comprising the pharmaceutical composition of the present invention.
  • the role of said vehicle is to allow the incorporation of other elements, allow better dosing and administration or to provide consistency and shape to the composition.
  • compositions can comprise from approximately 1% to approximately 95% active ingredient.
  • the pharmaceutical compositions of the present invention can comprise from approximately 20% to approximately 90% active ingredient (i.e., an IP5 substituted compound of the present invention or a combination thereof, alone or in combination, e.g., with one or more additional therapeutic agents).
  • Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient, e.g., an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53), combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline (e.g., a 0.9% (w/v) NaCl aqueous solution).
  • a pharmaceutically acceptable carrier such as sterile water or sterile isotonic saline (e.g., a 0.9% (w/v) NaCl aqueous solution).
  • Such formulations can be prepared, packaged, or sold in a form suitable for bolus administration or for non-bolus administration.
  • Injectable formulations can be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative.
  • Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations can further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • the active ingredient e.g., an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53), is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the pharmaceutical compositions can be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
  • This suspension or solution can be formulated according to the known art, and may comprise, in addition to the active ingredient (e.g., an inositol phosphate of the present invention), additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
  • Such sterile injectable formulations can be prepared using a non-toxic parenterally acceptable diluent or solvent, such as water or 1,3 -butanediol, for example.
  • Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides.
  • compositions for sustained release or implantation can comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
  • compositions and methods of making formulations for administering the IP5 substituted compounds of the present invention, including controlled- or sustained-release formulations containing the said active agents, are described in the art.
  • Medicaments according to the invention are manufactured by methods known in the art, especially by conventional mixing, coating, granulating, dissolving or lyophilizing.
  • the present invention also provides a compound or a combination of compounds or pharmaceutical formulation according to any of the above aspects of the invention, in the broadest definition given, or as specified in any of the aspects presented above, for use as a medicament.
  • the present invention also provides a compound or combination of compounds or pharmaceutical formulation according to any of the above aspects of the invention, in the broadest definition given, or as specified in any of the aspects presented above, for use in the treatment and/or prevention of a disease or condition disclosed herein.
  • the present invention also provides a compound or combination of compounds or pharmaceutical formulation according to any of the above aspects of the invention, in the broadest definition given, or as specified in any of the aspects presented above, for the manufacture of a medicament for the prevention and/or treatment of a disease or condition disclosed herein.
  • the present invention also provides articles of manufacture and kits.
  • Such articles of manufacture and kits can comprise a container (e.g., a box) comprising one or more vials containing a formulation comprising one or more of the IP5 substituted compounds of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) and/or solvents for their medical administration or other uses according to the methods disclosed herein.
  • kit or article of manufacture can also comprise brochures or instructions describing the process of medical administration and dosages disclosed herein, or the use of the IP5 substituted compounds of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) according to the methods disclosed herein.
  • kit or article of manufacture can comprise multiple vials, each one of them containing a single dose.
  • kit or article of manufacture can comprise one or more vials, each one of them comprising more than one dose.
  • the article of manufacture is a bag containing a solution of an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53).
  • the article of manufacture is a bottle (e.g., a glass bottle or a plastic bottle) containing a solution of an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53).
  • the article of manufacture is a bag containing an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) in powder form for reconstitution in an appropriate solvent.
  • the article of manufacture is a bottle (e.g., a glass bottle or a plastic bottle) containing an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) in powder form for reconstitution in an appropriate solvent.
  • an IP5 substituted compound of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • kits and articles of manufacture can include instructions for carrying out one or more administrations of the IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) according to the methods and dosages disclosed herein.
  • the IP5 substituted compound of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • kits and articles of manufacture can be affixed to packaging material or can be included as a package insert. While the instructions are typically written or printed materials, they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated. Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. As used herein, the term "instructions" can include the address of an internet site that provides the instructions.
  • the present invention provides methods for using the IP5 substituted compounds of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) to treat diseases and conditions.
  • the medical uses disclosed herein relate to the ability of the IP5 substituted compounds of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53) to inhibit the formation or growth of calcium salts/crystals (e.g., calcium phosphates, HAP) in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula I, or a pharmaceutical composition of disclosed herein.
  • the IP5 substituted compounds of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • the present invention provides methods to treat and/or prevent pathological crystallizations and/or the consequences thereof in a subject in need thereof comprising administering an IP5 substituted compound of the present invention (e.g., a compound selected from the group consisting of Compound 1 to Compound 53), wherein the administration of the IP5 substituted compound effectively treats and/or prevents pathological crystallization and/or the consequences thereof in the subject.
  • an IP5 substituted compound of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • the present invention also provides methods to manufacture a medicament for the treatment of pathological crystallization comprising using an intermediate compound selected from the group consisting of the compounds listed in Table 1. Also provided is a compound selected from the group consisting of Compound 1 to Compound 53 for the treatment of pathological crystallizations and/or the consequences thereof in a subject in need thereof.
  • the IP5 substituted compound of the present invention e.g., a compound selected from the group consisting of Compound 1 to Compound 53
  • Step 1 9-Methoxynonan-1-ol (6): A mixture of 9-bromononan-l-ol (0.5 g, 2.24 mmol) and sodium methoxide 4 N (25 mL, 100 mmol)) was stirred for 18 h at 40°C. The reaction mixture was filtered and concentrated in vacuum. The residue was purified by flash chromatography (silica gel, hexane (Hex):ethyl acetate (EtOAc) 4:1) to afford 324 mg of (6) (83% yield).
  • Step 2 9-Methoxynonyl 4-methylbenzenesulfonate (7): To a solution of (6) (1.5 g, 8.61 mmol) in (28.7 mL), TEA (1.80 mL, 12.91 mmol) and Ts-Cl (2.13 g, 11.19 mmol) were added. The reaction mixture was stirred for 24 h at rt then quenched with water and washed with brine. The organic layer was dried over with Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified by flash chromatography (silica gel, Hex:EtOAc 4:1) to afford 2.15 g of (7) (76%).
  • Step 1 2-((9-Bromononyl)oxy)tetrahvdro-2H-pyran (8): To a mixture of 9- bromononan-l-ol (2.18 g, 9.77 mmol) and p-TsOH (37 mg, 0.19 mmol), 3,4-dihydro-2H- pyran (1.3 mL, 14.65 mmol) was added. The reaction mixture was stirred for 3.5 days at 60°C. The mixture was diluted with water, extracted with ethyl ether (2x), dried over with Na 2 SO 4 , filtered, and the solvents removed in vacuo.
  • Step 3 IQ-Methoxydec-1-yne (10): To a (9) (8.17 g, 35.2 mmol), a solution 5 M of sodium methoxide in MeOH (35.2 mL, 176 mmol) was added. The reaction mixture was stirred for 18 h days at 45°C. The mixture was diluted with water, extracted with ethyl ether (2x), dried over with Na 2 SO 4 , filtered, and the solvents removed in vacuo. The residue was purified by flash chromatography (silica gel, Hex:EtOAc 20:1) rending 4 g of (10) (67% yield).
  • Step 4 2-((19-Methoxynonadec-10-vn-1-yl)oxy)tetrahvdro-2H-pyran (11): In an tetrahydrofurane (THF) and hexamethylphosphoramide (HMPA) mixed solution (1.2:1) of (10) (1.41 g, 8.42 mmol) cooled to -40° C., an Hex. solution 1.6M of n-BuLi (7.45 mL, 11.93 mmol) was slowly added, followed by stirring at the same temperature for 30 minutes and further stirring at 0°C for 30 minutes. After cooling to -20°C., a HMPA solution of (8) (2.16 g, 7.02 mmol) was slowly added.
  • THF tetrahydrofurane
  • HMPA hexamethylphosphoramide
  • Step 5 19-Methoxynonadec-lO-vn-1-ol (12): To a solution of (11) (3.28 g, 8.31 mmol) in MeOH (0.6M), p-TsOH (95 mg, 0.5 mmol) was added. The reaction mixture was stirred for 3.5 days at 60°C. The mixture was diluted with water, extracted with ethyl ether (2x), dried over with Na2SO4, filtered, and the solvents removed in vacuo. The filtrate was concentrated yielding 2.6 g of (12) (>99% yield).
  • Step 2 29-Methoxynonacosa-9,20-divn-1-ol
  • an n-hcxanc solution 1.6M of n-BuLi (1.9 mL, 3.09 mmol) was slowly added, followed by stirring at the same temperature for 30 minutes and further stirring at 0°C. for 30 minutes.
  • a HMPA solution of (14) (462 mg, 1.24 mmol) was slowly added. After stirring at the same temperature for 10 minutes, the temperature was increased to room temperature.
  • Step 3 29-Methoxynonacosa-9,20-divn-1-yl 4-methylbenzenesulfonate (16): To a solution of (15) (69.7 mg, 0.156 mmol) in DCM (0.1M) at 0°C, TEA (43uL, 0.325 mmol), DMAP (3.3 mg, 0.027 mmol) and Ts-Cl (62 mg, 0.325 mmol) were added. Then, the reaction mixture was diluted with water and tBuMeO. The organic layer was washed with sat aq NaHCO 3 and brine, dried over Na2SO 4 , filtered and the solvent was removed under reduced pressure to afford a yellow oil.
  • Step 1 6-Azidohexan-1-ol (21): A solution of 6-bromohexan-l-ol (428 pL, 3.27 mmol) and sodium azide (850 mg, 13.08 mmol) in DMF (0.8 M) was stirred for 18 h at 80°C. Then, the reaction mixture was quenched with water/EtOAc, and washed with brine (3x). The organic layer was dried over with Na 2 SO 4 , filtered, and concentrated in vacuum to afford 470 mg of (21) (>99%).
  • Step 1 N -(5-hydroxypentyl (acetamide (28): To a solution of 5-aminopentan-l- ol (50 g, 485 mmol) and 2,5-dioxopyrrolidin-l-yl acetate (75 g, 485 mmol) in dimethylformamide (DMF, 0.5 M), TEA (101 mL, 727 mmol) was added and the solution was stirred for 18 h at 60°C.
  • DMF dimethylformamide
  • Step 2 5-Acetamidopentyl 4-methylbenzenesulfonate (29): To a solution of (28) (70.4 g, 485 mmol) in DCM (0.5 M), TEA (101 mL, 727 mmol) and Ts-Cl (92 g, 485 mmol) were added. The reaction mixture was stirred for 18 h at rt, then, quenched with water/DCM and washed with NaHCO3sat and brine. The organic layer was dried over with Na 2 SO 4 , filtered and concentrated in vacuum to afford 92.45 g of (29) (63%).
  • Step 1 5-Azidopentan-1-ol (36): A solution of 5 -bromopentan- l-ol (0.10 mL, 0.89 mmol) and sodium azide (63 mg, 0.98 mmol) in dimethylformamide (DMF, 0.2 M) was stirred for 18 h at 80°C. Then, the reaction mixture was quenched with water/EtOAc and was washed with brine (3x). The organic layer was dried over with Na 2 SO 4 , filtered, and concentrated in vacuum to afford 57 mg of (36) (50%).
  • DMF dimethylformamide
  • Procedure K Alkyl-inositol derivative (II_B’, II_C, VIII_B’ or IX_D) was dissolved in a mixture of THF/MeOH (7:3, 0.05M) followed by addition of excess palladium hydroxide on carbon. The mixture was placed under hydrogen atmosphere and stirred 2 days at room temperature. The mixture was then purged with nitrogen, filtered and concentrated to afford the desired compounds.
  • reaction mixture was cooled at 0°C and a solution of tert-butyl hydroperoxide in hexane (5.5M) (19.2 eq) was added.
  • the solution was brought to room temperature and stirred for Ih.
  • the mixture was washed with dilute sodium sulfite and extracted with DCM.
  • the organic layer was dried over Na 2 SO 4 , filtered and concentrated in vacuum.
  • the residue was purified by flash chromatography (silica gel) to afford pure compounds.
  • reaction mixture was cooled at 0°C and a solution of tert-butyl hydroperoxide in hexane (5.5M) (24 eq) was added.
  • the solution was brought to room temperature and stirred for Ih.
  • the mixture was washed with dilute sodium sulfite and extracted with DCM.
  • the organic layer was dried over Na2SO4, filtered and concentrated in vacuum.
  • the residue was purified by flash chromatography (silica gel) to afford pure compounds.
  • reaction mixture was cooled at 0°C and a solution of tert-butyl hydroperoxide in hexane (5.5M) (24 eq) was added.
  • the solution was brought to room temperature and stirred for Ih.
  • the mixture was washed with dilute sodium sulfite and extracted with EtOAc (x2).
  • the organic layer was dried over Na2SO4, filtered and concentrated in vacuum.
  • the residue was purified by flash chromatography (silica gel) to afford pure compounds.
  • Procedure I Phosphorylated compound (IV_A, VII-A, IV_B, IV_C or IV_D) was dissolved in a mixture of THF/MeOH/Water (3:1: 1, 0.01M) followed by addition of excess palladium hydroxide on carbon or palladium on carbon. The mixture was placed under hydrogen atmosphere and stirred 2 days at room temperature. The mixture was then purged with nitrogen, filtered and concentrated. The compound was brought at pH 7 by addition of dilute aqueous NaOH (IN) and the residue was purified on a sephadex column (PD-10, G-25-M) by eluting with water. All fractions were lyophilized and analyzed by 1 H-RMN. The fractions containing product were purified further on a reverse phase cartridge (Sep-Pack, Waters, 1g, C18) by eluting with water. All fractions were lyophilized and analyzed by 1 H-RMN.
  • Procedure J Phosphorylated compound (IV_A, VII-A, IV_B, IV_C or IV_D) was dissolved in a mixture of THF/MeOH/Water (3:1: 1, 0.01M) followed by addition of excess palladium hydroxide on carbon or palladium on carbon. The mixture was placed under hydrogen atmosphere and stirred 2 days at room temperature. The mixture was then purged with nitrogen, filtered and concentrated. The compound was brought at pH 10 by addition of dilute aqueous NaOH (IN) and the solution was stirred for 24-48h. Finally, the solution was purified on a sephadex column (PD-10, G-25-M) by eluting with water. All fractions were lyophilized and analyzed by 1 H-RMN. The fractions containing product were purified further on a reverse phase cartridge (Sep-Pack, Waters, 1g, Cl 8) by eluting with water. All fractions were lyophilized and analyzed by 1 H-RMN.
  • a sephadex column
  • Procedure T Phosphorylated compound (IV_A, VII-A, IV_B, IV_C or IV_D) was treated with thiophenol (40 eq), m-cresol (40 eq) in TFA (0.045 M). Then TBMSBr (40 eq) was added slowly and the mixture was stirred at rt for 4h, quenched with water, and extracted with DCM (3x). The aqueous layer was concentrated in vacuum. The residue was brought at pH 9-10 by addition of water and dilute aqueous NaOH (IN), and the compound was purified on a sephadex column (PD-10, G-25-M) by eluting with water.
  • V_C-1 5-0-(5-Azidopentyl)-l,2,3,4,6-penta-0-benzyl-myo- inositol
  • V_D-1) According to general alkylation Procedure B, from 285 mg of (34) and 254 mg (1.5 eq) of (37), 351mg mg of (V_D-1) were obtained (>99% yield).
  • HPLC-MS (Condition A): rt 5.55 min; m/z: 610 [M+23] + .
  • Condition A High-performance Liquid Chromatography (HPLC) 2795 Alliance Waters Aquity coupled to Detector DAD Agilent 1100 and Detector MS Waters ESI triple cuadrupolo Quattro micro, 10 pL of sample in MeOH was injected.
  • Mass spectroscopy (MS) analyzed by FIA (flux injected analysis) coupled to LCT Premier Orthogonal Accelerated Time of Flight Mass Spectrometer, acquiring data by electrospray ionization (ESI) in positive mode. Spectra have been scanned between 50 and 1500 Da with values every 0.2 seconds and peaks are given m/z (% of basis peak).
  • Stationary phase ZORBAX Extend-C18 3.5 pm 2.1 x 50 mm (T a 35°C).
  • IP5 substituted compounds e.g., Compounds 1 to 32
  • the in vitro efficacy of the IP5 substituted compounds (e.g., Compounds 1 to 32) of the invention on the inhibition of calcium phosphate crystallization in human plasma samples was evaluated according to a spectrophotometric assay previously described in the art (Ferrer M, et al., Sci Rep 2017; 7:6858, doi:10.1038/s41598-017-07203-x).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés substitués par IP5 de formule générale I, leurs procédés de synthèse et leurs utilisations. Les composés substitués par IP5 de l'invention sont caractérisés pour avoir des chaînes -O(alkyl)nX, et-O(alkyl)yCy(alkyl)y'-Z dans les positions R1, R2, R4 et R5. L'invention concerne également des procédés, des compositions pharmaceutiques et des formulations, des procédés d'utilisation, des articles manufacturés et des kits pour le traitement de maladies et d'états tels que des maladies et des états pathologiques liés à la cristallisation pathologique.
PCT/EP2023/071141 2022-07-29 2023-07-31 Composés substitués par ip5 Ceased WO2024023360A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP23750984.9A EP4562019A1 (fr) 2022-07-29 2023-07-31 Composés substitués par ip5
CN202380056920.2A CN119630679A (zh) 2022-07-29 2023-07-31 Ip5取代的化合物
KR1020257006598A KR20250049546A (ko) 2022-07-29 2023-07-31 Ip5 치환된 화합물
IL318651A IL318651A (en) 2022-07-29 2023-07-31 Ip5-substituted compounds
CA3263493A CA3263493A1 (fr) 2022-07-29 2023-07-31 Composés substitués par ip5
JP2025505402A JP2025525098A (ja) 2022-07-29 2023-07-31 Ｉｐ５置換化合物
AU2023313051A AU2023313051A1 (en) 2022-07-29 2023-07-31 Ip5 substituted compounds
MX2025001128A MX2025001128A (es) 2022-07-29 2025-01-27 Compuestos sustituidos de ip5

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22382737 2022-07-29
EP22382737.9 2022-07-29

Publications (1)

Publication Number Publication Date
WO2024023360A1 true WO2024023360A1 (fr) 2024-02-01

Family

ID=83319363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/071141 Ceased WO2024023360A1 (fr) 2022-07-29 2023-07-31 Composés substitués par ip5

Country Status (11)

Country Link
EP (1) EP4562019A1 (fr)
JP (1) JP2025525098A (fr)
KR (1) KR20250049546A (fr)
CN (1) CN119630679A (fr)
AR (1) AR130072A1 (fr)
AU (1) AU2023313051A1 (fr)
CA (1) CA3263493A1 (fr)
IL (1) IL318651A (fr)
MX (1) MX2025001128A (fr)
TW (1) TW202412815A (fr)
WO (1) WO2024023360A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162971A1 (fr) * 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Composés ip5 substitués destinés à être utilisés dans le traitement, l'inhibition de la progression et la prévention de la calcification ectopique

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011757A1 (fr) 1989-04-11 1990-10-18 Depomed Systems, Inc. Forme de posologie orale de medicament a liberation entretenue
WO1993018755A1 (fr) 1992-03-25 1993-09-30 Depomed Systems, Incorporated Formes galeniques de medicament oral a liberation prolongee a base de cellulose a substitution alkyle
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (fr) 1996-06-10 1997-12-18 Depomed, Inc. Systeme a caracteristiques de retention renforcees pour l'administration controlee par voie orale de medicaments a retention gastrique
WO1998011879A1 (fr) 1996-09-19 1998-03-26 Depomed, Inc. Formes galeniques orales retenues dans l'estomac, pour la liberation controlee de medicaments faiblement solubles et de substance insoluble
WO1998055107A1 (fr) 1997-06-06 1998-12-10 Depomed, Inc. Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles
WO2001032217A2 (fr) 1999-11-02 2001-05-10 Depomed, Inc. Declenchement pharmacologique du mode par ingestion pour une administration amelioree de medicaments dans l'estomac
WO2001056544A2 (fr) 2000-02-04 2001-08-09 Depomed, Inc. Forme posologique enveloppe et noyau approchant la liberation d'ordre zero du medicament
WO2001097783A1 (fr) 2000-06-20 2001-12-27 Depomed, Inc. Comprimes destines a accroitre la retention gastrique de formes posologiques orales gonflantes a liberation controlee
WO2002032416A2 (fr) 2000-10-17 2002-04-25 Depomed, Inc. Inhibition d'effet emetique de metformine avec des antagonistes du recepteur 5-ht3
WO2002096404A1 (fr) 2001-05-29 2002-12-05 Depomed Development Ltd Methode de traitement de reflux gastroesophagien pathologique et de secretion d'acide nocturne
US20030039688A1 (en) 1997-06-06 2003-02-27 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO2003035029A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Formulation d'une forme posologique erodable a administration orale et a retention gastrique utilisant des donnees d'essai de desintegration in vitro
WO2003035177A2 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Melanges polymeres optimaux pour comprimes a retention gastrique
WO2003035039A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Traitement utilisant une dose posologique de losartan a retention gastrique
WO2003035041A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Forme posologique a administration orale a retention gastrique a liberation limitee dans le tractus gastro-intestinal inferieur
WO2003035040A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Methodes de traitement a l'aide d'un dosage de gabapentine a retenue gastrique
US20030147952A1 (en) 2002-02-01 2003-08-07 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20060241308A1 (en) * 2005-04-26 2006-10-26 Berry & Associates, Inc. Probe for measuring phytase activity
US20070066574A1 (en) 2003-11-07 2007-03-22 Felicia Grases Freixedas Myo-inositol hexaphosphate for topical use
WO2009061393A1 (fr) 2007-11-05 2009-05-14 Berry & Associates, Inc. Sonde pour mesurer une activité de phytase
WO2011064559A2 (fr) 2009-11-30 2011-06-03 Queen Mary And Westfield College, University Of London Dérivés inédits du phosphate d'inositol
US8377909B2 (en) 2006-06-01 2013-02-19 Universitat De Les Illes Balears Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis
US8778912B2 (en) 2008-08-06 2014-07-15 Universitat De Les Illes Balears Composition of dialysis liquid comprising crystallisation inhibitor substances
US9612250B2 (en) 2011-10-06 2017-04-04 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
WO2017098047A1 (fr) 2015-12-11 2017-06-15 ETH Zürich Dérivés d'inositol à utiliser dans la cristallisation pathologique
WO2020058321A1 (fr) 2018-09-18 2020-03-26 Inositec Ag Inhibiteurs de cristallisation d'oxalate de calcium pour troubles rénaux
WO2021219135A1 (fr) 2020-04-30 2021-11-04 上海森辉医药有限公司 Dérivé d'inositol et son utilisation

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011757A1 (fr) 1989-04-11 1990-10-18 Depomed Systems, Inc. Forme de posologie orale de medicament a liberation entretenue
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1993018755A1 (fr) 1992-03-25 1993-09-30 Depomed Systems, Incorporated Formes galeniques de medicament oral a liberation prolongee a base de cellulose a substitution alkyle
WO1997047285A1 (fr) 1996-06-10 1997-12-18 Depomed, Inc. Systeme a caracteristiques de retention renforcees pour l'administration controlee par voie orale de medicaments a retention gastrique
WO1998011879A1 (fr) 1996-09-19 1998-03-26 Depomed, Inc. Formes galeniques orales retenues dans l'estomac, pour la liberation controlee de medicaments faiblement solubles et de substance insoluble
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US20020051820A1 (en) 1997-06-06 2002-05-02 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (fr) 1997-06-06 1998-12-10 Depomed, Inc. Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles
US6340475B2 (en) 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US20030039688A1 (en) 1997-06-06 2003-02-27 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO2001032217A2 (fr) 1999-11-02 2001-05-10 Depomed, Inc. Declenchement pharmacologique du mode par ingestion pour une administration amelioree de medicaments dans l'estomac
US20030044466A1 (en) 1999-11-02 2003-03-06 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
WO2001056544A2 (fr) 2000-02-04 2001-08-09 Depomed, Inc. Forme posologique enveloppe et noyau approchant la liberation d'ordre zero du medicament
US20030104062A1 (en) 2000-02-04 2003-06-05 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
WO2001097783A1 (fr) 2000-06-20 2001-12-27 Depomed, Inc. Comprimes destines a accroitre la retention gastrique de formes posologiques orales gonflantes a liberation controlee
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002032416A2 (fr) 2000-10-17 2002-04-25 Depomed, Inc. Inhibition d'effet emetique de metformine avec des antagonistes du recepteur 5-ht3
WO2002096404A1 (fr) 2001-05-29 2002-12-05 Depomed Development Ltd Methode de traitement de reflux gastroesophagien pathologique et de secretion d'acide nocturne
US20030104053A1 (en) 2001-10-25 2003-06-05 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
WO2003035041A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Forme posologique a administration orale a retention gastrique a liberation limitee dans le tractus gastro-intestinal inferieur
WO2003035040A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Methodes de traitement a l'aide d'un dosage de gabapentine a retenue gastrique
WO2003035177A2 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Melanges polymeres optimaux pour comprimes a retention gastrique
WO2003035029A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Formulation d'une forme posologique erodable a administration orale et a retention gastrique utilisant des donnees d'essai de desintegration in vitro
WO2003035039A1 (fr) 2001-10-25 2003-05-01 Depomed, Inc. Traitement utilisant une dose posologique de losartan a retention gastrique
US20030147952A1 (en) 2002-02-01 2003-08-07 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20070066574A1 (en) 2003-11-07 2007-03-22 Felicia Grases Freixedas Myo-inositol hexaphosphate for topical use
US20060241308A1 (en) * 2005-04-26 2006-10-26 Berry & Associates, Inc. Probe for measuring phytase activity
US8377909B2 (en) 2006-06-01 2013-02-19 Universitat De Les Illes Balears Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis
WO2009061393A1 (fr) 2007-11-05 2009-05-14 Berry & Associates, Inc. Sonde pour mesurer une activité de phytase
US8778912B2 (en) 2008-08-06 2014-07-15 Universitat De Les Illes Balears Composition of dialysis liquid comprising crystallisation inhibitor substances
WO2011064559A2 (fr) 2009-11-30 2011-06-03 Queen Mary And Westfield College, University Of London Dérivés inédits du phosphate d'inositol
US9612250B2 (en) 2011-10-06 2017-04-04 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
WO2017098047A1 (fr) 2015-12-11 2017-06-15 ETH Zürich Dérivés d'inositol à utiliser dans la cristallisation pathologique
WO2020058321A1 (fr) 2018-09-18 2020-03-26 Inositec Ag Inhibiteurs de cristallisation d'oxalate de calcium pour troubles rénaux
WO2021219135A1 (fr) 2020-04-30 2021-11-04 上海森辉医药有限公司 Dérivé d'inositol et son utilisation

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"Concise Dictionary of Biomedicine and Molecular", 2002, CRC PRESS
"Oxford Dictionary of Biochemistry and Molecular Biology", 2000, OXFORD UNIVERSITY PRESS
"The Dictionary of Cell and Molecular Biology", 1999, ACADEMIC PRESS
AIBA T ET AL., ORG BIOMOL CHEM, vol. 14, no. 28, 2016, pages 6672 - 6675
AXGYAL S J ET AL: "CYCLITOLS XXIX.* POLYPHOSPHORYLATION OF POLYOLS. THE SYNTHESIS OF MYO-INOSITOL PENTAPHOSPHATES", AUSTRALIAN JOURNAL OF CHEMISTRY, 1 January 1969 (1969-01-01), pages 391 - 404, XP093014940, Retrieved from the Internet <URL:https://www.publish.csiro.au/CH/pdf/CH9690391> [retrieved on 20230118] *
BERRY D F ET AL: "Tethered phytic acid as a probe for measuring phytase activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 15, no. 12, 15 June 2005 (2005-06-15), pages 3157 - 3161, XP027801699, ISSN: 0960-894X, [retrieved on 20050615] *
BEVILACQUA M ET AL., LUPUS, vol. 14, 2005, pages 773 - 779
CHEN W ET AL., EUR J MED CHEM, vol. 93, 2015, pages 172 - 181
DATABASE REAXYS [online] 1 January 1969 (1969-01-01), ANGYAL S J: "Australian Journal of Chemistry; vol. 22; (1969); p. 391 - 404", XP093014941, Database accession no. XRN = 2495913, 3191734 *
FALASCA1 M ET AL: "A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP UK, LONDON, vol. 102, no. 1, 5 January 2010 (2010-01-05), pages 104 - 114, XP002628330, ISSN: 0007-0920, DOI: 10.1038/SJ.BJC.6605408 *
FERRER M ET AL., SCI REP, vol. 7, 2017, pages 6858
GRASES F ET AL., CIR J, vol. 71, 2007, pages 1152 - 1156
GRASES F ET AL., FRONT BIOSCI, vol. 11, 2006, pages 136 - 142
GRUBE A ET AL., EUR J ORG CHEM, 2006, pages 1285 - 1295
GURALE B ET AL., CARBOHYDRATE RES, vol. 461, 2018, pages 38 - 44
HANBALI M. ET AL., BIOORG MED CHEM LETTERS, vol. 16, no. 10, 2006, pages 2637 - 2640
HAYNES M ET AL., J. PHARMACEUTICAL SCI, vol. 94, 2005, pages 2111 - 2120
HUANG X ET AL., ACS APPL MATER INTERFACES, vol. 9, 2017, pages 10435 - 10445
HUANG XIANGANG ET AL: "Characterization of Calcium Phosphate Nanoparticles Based on a PEGylated Chelator for Gene Delivery", vol. 9, no. 12, 14 March 2017 (2017-03-14), US, pages 10435 - 10445, XP093014942, ISSN: 1944-8244, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsami.6b15925> DOI: 10.1021/acsami.6b15925 *
JESÚS R. MEDINA: "Selective 3-Phosphoinositide-Dependent Kinase 1 (PDK1) Inhibitors: Dissecting the Function and Pharmacology of PDK1", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 7, 11 April 2013 (2013-04-11), pages 2726 - 2737, XP055156409, ISSN: 0022-2623, DOI: 10.1021/jm4000227 *
KARDIVEL M, ORG BIOMOL CHEM, vol. 6, no. 11, 2008, pages 1966 - 1972
KHAN S ET AL.: "Hydroxyapatite and Related Materials", 1994, CRC PRESS, article "Pathological crystallization of calcium oxalate and calcium phosphate"
LANGMUIR: THE ACS JOURNAL OF SURFACES AND COLLOIDS., vol. 29, no. 2, 2013, pages 570 - 580
LOMASHVILI K ET AL., J AM SOC NEPHROL, vol. 15, 2004, pages 1392 - 1401
MARTIN S ET AL., J ORG CHEM, vol. 59, no. 17, 1994, pages 4805 - 4820
MARTIN S ET AL., J. ORG. CHEM., vol. 59, no. 17, 1994, pages 4805 - 4820
PHENIX C ET AL., CHEMBIOCHEM, vol. 9, no. 10, 2008, pages 1591 - 1602
PRICE P ET AL., ARTERIOSCLER THROMB VASC BIOL, vol. 21, 2001, pages 817 - 824
PRICE P ET AL., J NUTR, vol. 131, 2001, pages 2910 - 2915
SONG F ET AL., ORG BIOMOL CHEM, vol. 10, 2012, pages 3642 - 3654
WANG H ET AL., CHEM BIOL, vol. 21, 2014, pages 689 - 699
WANG HUANCHEN ET AL: "Synthetic Inositol Phosphate Analogs Reveal that PPIP5K2 Has a Surface-Mounted Substrate Capture Site that Is a Target for Drug Discovery", CHEMISTRY & BIOLOGY, vol. 21, no. 5, 1 May 2014 (2014-05-01), GB, pages 689 - 699, XP093014939, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2014.03.009 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162971A1 (fr) * 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Composés ip5 substitués destinés à être utilisés dans le traitement, l'inhibition de la progression et la prévention de la calcification ectopique

Also Published As

Publication number Publication date
TW202412815A (zh) 2024-04-01
CA3263493A1 (fr) 2024-02-01
EP4562019A1 (fr) 2025-06-04
AU2023313051A1 (en) 2025-02-13
AR130072A1 (es) 2024-10-30
MX2025001128A (es) 2025-03-07
JP2025525098A (ja) 2025-08-01
IL318651A (en) 2025-03-01
KR20250049546A (ko) 2025-04-11
CN119630679A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
AU2014212487B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
US3074992A (en) Novel cyclic phosphoric acid ester amides, and the production thereof
AU2015210452A1 (en) N-acylsulfonamide apoptosis promoters
EP3613420B1 (fr) Sels et promédicaments de 1-méthyl-d-tryptophane
CA3119957A1 (fr) Nouveau derive d&#39;imidazole
WO2024023360A1 (fr) Composés substitués par ip5
US5298499A (en) S-2-(substituted ethylamino)ethyl phosphorothioates
US20240109924A1 (en) Ip4-4,6 substituted derivative compounds
WO2012150866A1 (fr) Inhibiteurs de phosphoribosyltransférases et leurs utilisations
KR20220005554A (ko) 전구약물 화합물
EP4561585A1 (fr) Composés dérivés substitués en ip4-4,6 destinés à être utilisés dans le traitement, l&#39;inhibition de la progression et la prévention de la calcification ectopique
WO2025162971A1 (fr) Composés ip5 substitués destinés à être utilisés dans le traitement, l&#39;inhibition de la progression et la prévention de la calcification ectopique
AU2006277682A1 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
FI90982B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten mitomysiinifosfaattijohdannaisten valmistamiseksi
AU2017301488A1 (en) Pantetheine derivatives for the treatment of neurologic disorders
WO2018085263A1 (fr) Composés pour le traitement de maladies neurodégénératives
IL303704A (en) Processes for the preparation of soluble salts of inositol phosphates
HK40094155A (zh) Ip4-4，6取代的衍生化合物
EP4647435A1 (fr) Modulateur pour favoriser la liaison de la butyrophiline 3a1/2a1
JP2026503047A (ja) ブチロフィリン３ａ１／２ａ１の結合を促進するための調節物質
WO2017137895A1 (fr) Nouvelles pyrrolidines dendrimères, leur synthèse et utilisation médicale
CA3241259A1 (fr) Analogues de pyridoxal-5-phosphate (p5p)
KR20230017149A (ko) TNF-α생성 및 염증 복합체 활성 억제 신규 화합물 및 이의 제조방법
JP2025513630A (ja) 休眠状態の細菌細胞を除去する抗菌性化合物
Kim Synthesis of structurally modified phospholipids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750984

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380056920.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/001128

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 318651

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: AU2023313051

Country of ref document: AU

Ref document number: 2025505402

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202590355

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025001725

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2023313051

Country of ref document: AU

Date of ref document: 20230731

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202547014537

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20257006598

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023750984

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023750984

Country of ref document: EP

Effective date: 20250228

WWP Wipo information: published in national office

Ref document number: 202547014537

Country of ref document: IN

Ref document number: MX/A/2025/001128

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202380056920.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020257006598

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 202590355

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2023750984

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112025001725

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250128